129 related articles for article (PubMed ID: 25571292)
1. A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Methaneethorn J; Chamnansua M; Kaewdang N; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5711-4. PubMed ID: 25571292
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans.
Methaneethorn J; Kunyamee P; Jindasri W; Wattanasaovaluk W; Kraiboot A; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5715-8. PubMed ID: 25571293
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans.
Methaneethorn J; Chaiwong K; Pongpanich K; Sonsingh P; Lohitnavy M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5703-6. PubMed ID: 25571290
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi DH; Li C; Choi JS
Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):163-8. PubMed ID: 20166433
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole.
Lohitnavy M; Methaneethorn J; Chiang-Ngernthanyakool R; Tongpeng W; Chan-Im D; Phaohorm S
Annu Int Conf IEEE Eng Med Biol Soc; 2015; 2015():3246-9. PubMed ID: 26736984
[TBL] [Abstract][Full Text] [Related]
7. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407
[TBL] [Abstract][Full Text] [Related]
8. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Aug; 64(2):177-82. PubMed ID: 9728898
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension.
Watanabe H; Kosuge K; Nishio S; Yamada H; Uchida S; Satoh H; Hayashi H; Ishizaki T; Ohashi K
Life Sci; 2004 Dec; 76(3):281-92. PubMed ID: 15531380
[TBL] [Abstract][Full Text] [Related]
11. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.
Nishio S; Watanabe H; Kosuge K; Uchida S; Hayashi H; Ohashi K
Hypertens Res; 2005 Mar; 28(3):223-7. PubMed ID: 16097365
[TBL] [Abstract][Full Text] [Related]
12. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
13. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine.
Son H; Lee D; Lim LA; Jang SB; Roh H; Park K
Drug Metab Pharmacokinet; 2014; 29(2):120-8. PubMed ID: 23965645
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
15. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
16. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
18. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Nov; 64(5):477-83. PubMed ID: 9834039
[TBL] [Abstract][Full Text] [Related]
19. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
[TBL] [Abstract][Full Text] [Related]
20. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
Dadashzadeh S; Javadian B; Sadeghian S
Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
